LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 285

Search options

  1. Article ; Online: Revival of cytokine therapy in heart failure?

    Kastrup, Jens

    European heart journal

    2015  Volume 36, Issue 44, Page(s) 3070–3073

    MeSH term(s) Cytokines ; Heart Failure/therapy ; Humans
    Chemical Substances Cytokines
    Language English
    Publishing date 2015-11-21
    Publishing country England
    Document type Comment ; Editorial
    ZDB-ID 603098-1
    ISSN 1522-9645 ; 0195-668X
    ISSN (online) 1522-9645
    ISSN 0195-668X
    DOI 10.1093/eurheartj/ehv515
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1563: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 640: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book ; Thesis: The diabetic arteriole

    Kastrup, Jens

    the impact of diabetic microangiopathy on microcirculatory control

    1988  

    Keywords Diabetic Angiopathies ; Microcirculation
    Size 16 S. : graph. darst.
    Publishing country Denmark
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Kopenhagen, Univ., Diss., 1988
    HBZ-ID HT003290819
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    89 E 879 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?

    Kastrup, Jens

    Immunobiology

    2012  Volume 217, Issue 5, Page(s) 483–491

    Abstract: Coronary artery disease is the most common background of death in western countries. Medical therapies and revisualization by percutaneous coronary intervention or coronary by-pass surgery have reduced the mortality significantly. However, many of the ... ...

    Abstract Coronary artery disease is the most common background of death in western countries. Medical therapies and revisualization by percutaneous coronary intervention or coronary by-pass surgery have reduced the mortality significantly. However, many of the treated patients still have angina or heart failure symptoms, many hospitalisations and a poor prognosis. Therefore, there is need for identifying new biomarkers, which alone or in combination with other risk markers are useful in monitoring treatment and as prognostic markers for future cardiovascular events in patients with ischemic heart disease. The inflammatory biomarker YKL-40 has recently been found elevated in patients with both acute and stable chronic cardiovascular diseases. Therefore, YKL-40 could potentially be a new useful biomarker of disease severity, prognosis and survival in patients with ischemic heart disease. The review will present published information about YKL40 in cardiac patients and discuss whether YKL-40 could be used for monitoring the therapies and for prognostic evaluations in patients with cardiovascular disease.
    MeSH term(s) Adipokines/immunology ; Biomarkers ; Cardiovascular Diseases/immunology ; Chitinase-3-Like Protein 1 ; Humans ; Inflammation/immunology ; Lectins/immunology
    Chemical Substances Adipokines ; Biomarkers ; CHI3L1 protein, human ; Chitinase-3-Like Protein 1 ; Lectins
    Language English
    Publishing date 2012-05
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 563292-4
    ISSN 1878-3279 ; 0171-2985
    ISSN (online) 1878-3279
    ISSN 0171-2985
    DOI 10.1016/j.imbio.2011.04.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ud II Zs.32: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Investigating the paracrine and juxtacrine abilities of adipose-derived stromal cells in angiogenesis triple cell co-cultures.

    Harary Søndergaard, Rebekka / Drozd Højgaard, Lisbeth / Haack-Sørensen, Mandana / Hoeeg, Cecilie / Mønsted Johansen, Ellen / Follin, Bjarke / Kastrup, Jens / Ekblond, Annette / Juhl, Morten

    Stem cell research

    2024  Volume 77, Page(s) 103417

    Abstract: The pro-angiogenic abilities of adipose-derived stromal cells (ASCs) make them attractive candidates for cellular therapy, especially for ischemic disease indications. However, details regarding the underlying mechanisms remain elusive. Therefore, this ... ...

    Abstract The pro-angiogenic abilities of adipose-derived stromal cells (ASCs) make them attractive candidates for cellular therapy, especially for ischemic disease indications. However, details regarding the underlying mechanisms remain elusive. Therefore, this study aimed to investigate paracrine and juxtacrine abilities of ASCs in angiogenesis triple cell co-cultures by detailed image analysis of the vascular-like structures. Fibroblast-endothelial cell co-cultures were established, and ASCs were added directly or indirectly through inserts. The cultures were treated with antibodies or subjected to analyses using ELISA and RT
    Language English
    Publishing date 2024-04-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 2393143-7
    ISSN 1876-7753 ; 1873-5061
    ISSN (online) 1876-7753
    ISSN 1873-5061
    DOI 10.1016/j.scr.2024.103417
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Optimizing an immunomodulatory potency assay for Mesenchymal Stromal Cell.

    Hansen, Stine Bangsgaard / Højgaard, Lisbeth Drozd / Kastrup, Jens / Ekblond, Annette / Follin, Bjarke / Juhl, Morten

    Frontiers in immunology

    2022  Volume 13, Page(s) 1085312

    Abstract: The expeditious progress of Mesenchymal Stromal Cells (MSC) for therapeutic intervention calls for means to compare differences in potency of cell products. The differences may be attributed to innumerable sources including tissue origin, production ... ...

    Abstract The expeditious progress of Mesenchymal Stromal Cells (MSC) for therapeutic intervention calls for means to compare differences in potency of cell products. The differences may be attributed to innumerable sources including tissue origin, production methods, or even between batches. While the immunomodulatory potential of MSC is recognized and well-documented by an expansive body of evidence, the methodologies and findings vary markedly. In this study, we utilized flowcytometric analysis of lymphocyte proliferation based on cryopreserved peripheral blood mononuclear cells for quantification of the inhibitory effect of MSC. Technical aspects of fluorescent staining and cryopreservation of peripheral blood mononuclear cells were evaluated to obtain optimal results and increase feasibility. A range of common specific and unspecific mitogens was titrated to identify the conditions, in which the effects of Adipose tissue-derived Stromal Cells (ASC; a type of MSC) were most pronounced. Specific stimulation by antibody-mediated activation of CD3 and CD28
    MeSH term(s) Leukocytes, Mononuclear ; Cells, Cultured ; Mesenchymal Stem Cells/metabolism ; Immunomodulation ; Stromal Cells ; Mitogens
    Chemical Substances Mitogens
    Language English
    Publishing date 2022-12-12
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2022.1085312
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: GMP Compliant Production of a Cryopreserved Adipose-Derived Stromal Cell Product for Feasible and Allogeneic Clinical Use.

    Haack-Sørensen, Mandana / Johansen, Ellen Mønsted / Højgaard, Lisbeth Drozd / Kastrup, Jens / Ekblond, Annette

    Stem cells international

    2022  Volume 2022, Page(s) 4664917

    Abstract: The emerging field of advanced therapy medicinal products (ATMP) holds promise of treating a variety of diseases. Adipose-derived stromal cells (ASCs) are currently being marketed or tested as cell-based therapies in numerous clinical trials. To ensure ... ...

    Abstract The emerging field of advanced therapy medicinal products (ATMP) holds promise of treating a variety of diseases. Adipose-derived stromal cells (ASCs) are currently being marketed or tested as cell-based therapies in numerous clinical trials. To ensure safety and efficacy of treatments, high-quality products must be manufactured. A good manufacturing practice (GMP) compliant and consistent manufacturing process including validated quality control methods is critical. Product design and formulation are equally important to ensure clinical feasibility. Here, we present a GMP-compliant, xeno-free, and semiautomated manufacturing process and quality controls, used for large-scale production of a cryopreserved off-the-shelf ASC product and tested in several phase I and II allogeneic clinical applications.
    Language English
    Publishing date 2022-06-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2573856-2
    ISSN 1687-9678 ; 1687-966X
    ISSN (online) 1687-9678
    ISSN 1687-966X
    DOI 10.1155/2022/4664917
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Stem cells therapy for cardiovascular repair in ischemic heart disease: How to predict and secure optimal outcome?

    Kastrup, Jens

    The EPMA journal

    2011  Volume 2, Issue 1, Page(s) 107–117

    Abstract: Coronary artery disease is a growing problem worldwide. Early treatment with stabilizing drugs and revascularization by percutaneous coronary intervention or by-pass surgery has reduced the mortality significantly, but it is still the most common cause ... ...

    Abstract Coronary artery disease is a growing problem worldwide. Early treatment with stabilizing drugs and revascularization by percutaneous coronary intervention or by-pass surgery has reduced the mortality significantly, but it is still the most common cause of death and a major cause of hospital admissions in industrialized countries. Treatment with stem cells with the potential to regenerate the damaged myocardium is a relatively new approach. However, the results from clinical studies on stem cell therapy for cardiac regeneration in patients with acute or chronic ischemic heart disease have been inconsistent. Some of the discrepancy could be due differences in study designs or patient selection. The review will based on conducted clinical stem cell trials try to elucidate how to predict and personalize this new treatment approach.
    Language English
    Publishing date 2011-02-08
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2545928-4
    ISSN 1878-5085 ; 1878-5077
    ISSN (online) 1878-5085
    ISSN 1878-5077
    DOI 10.1007/s13167-011-0062-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Functional in vitro models of the inhibitory effect of adipose tissue-derived stromal cells on lymphocyte proliferation: Improved sensitivity and quantification through flow cytometric analysis.

    Juhl, Morten / Follin, Bjarke / Christensen, Jan Pravsgaard / Kastrup, Jens / Ekblond, Annette

    Journal of immunological methods

    2022  Volume 510, Page(s) 113360

    Abstract: As the interest in cell-based therapies continue to increase, so does the need for assays detailing potency and providing platforms for identifying mechanisms of action. For most clinical implications of mesenchymal stromal cells, the immunomodulatory ... ...

    Abstract As the interest in cell-based therapies continue to increase, so does the need for assays detailing potency and providing platforms for identifying mechanisms of action. For most clinical implications of mesenchymal stromal cells, the immunomodulatory effect is crucial. While the suppressive potential on lymphocyte proliferation is well-described in literature, reproducible and standardized assays to document and quantify it varies from research group to research group and between methodologies. The aim of the present study was to utilize flowcytometry to quantify proliferation and identify measurements to increase the assay sensitivity to treatment with adipose tissue-derived stromal cells (ASC). Lymphocyte proliferation was induced by the unspecific mitogen phytohemagglutinin or by alloreactivity towards an irradiated donor in a mixed lymphocyte reaction. Addition of ASC did not change the composition of T cells, B cells, NK cells, NKT cell types considerably; likewise, no increases in proliferation were observed upon inclusion of ASC, demonstrating that ASC does not evoke an additive response. On the contrary, the suppressive effect of ASC was documented. By applying different gating strategies and curve fitting, the sensitivity was increased, and dose-response relationships established. Flow cytometric evaluation allows for more detailed identification of the lymphocytes affected by ASC and constitute a significant asset in future unraveling of modes and mechanisms of action, as well as quantification of potency.
    MeSH term(s) Adipose Tissue ; Cell Proliferation ; Cells, Cultured ; Mitogens ; Phytohemagglutinins/pharmacology ; Stromal Cells/metabolism
    Chemical Substances Mitogens ; Phytohemagglutinins
    Language English
    Publishing date 2022-09-18
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 120142-6
    ISSN 1872-7905 ; 0022-1759
    ISSN (online) 1872-7905
    ISSN 0022-1759
    DOI 10.1016/j.jim.2022.113360
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 795: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Long-Term Outcome Following Treatment With Allogeneic Mesenchymal Stem/Stromal Cells for Radiation-Induced Hyposalivation and Xerostomia.

    Jakobsen, Kathrine Kronberg / Lynggaard, Charlotte Duch / Paaske, Natasja / Carlander, Amanda-Louise Fenger / Kastrup, Jens / Hauge, Anne Werner / Christensen, Robin / Grønhøj, Christian / Buchwald, Christian von

    Stem cells translational medicine

    2024  

    Abstract: Background: Adipose-derived mesenchymal stem/stromal cells (ASCs) are proposed as a new xerostomia treatment. The study evaluated the long-term safety and effectiveness of allogeneic ASCs in radiation-induced xerostomia among patients with previous ... ...

    Abstract Background: Adipose-derived mesenchymal stem/stromal cells (ASCs) are proposed as a new xerostomia treatment. The study evaluated the long-term safety and effectiveness of allogeneic ASCs in radiation-induced xerostomia among patients with previous oropharyngeal cancer.
    Methods: This study constitutes 3-year follow-up on the original 10 patients who received allogeneic ASCs injections to the submandibular and parotid glands as part of the MESRIX-II trial. The MESRIX-II trial included the preliminary 4-month follow-up. The primary endpoint was long-term safety. Secondary endpoints were effectiveness evaluated by changes in salivary flow rate and patient-reported outcomes (PROs). Immune response was evaluated by assessing the development of donor-specific antibodies (DSA).
    Findings: All 10 MESRIX-II patients completed the long-term follow-up (ie, no missing data). During the long-term follow-up, 2 patients encountered a significant adverse event, which was determined to be unrelated to the treatment. No DSAs were detectable at 3 years. The stimulated salivary flow rate increased significantly from an average of 0.66 mL/minute at baseline to 0.86 mL/minute at follow-up, corresponding to an increase of 0.20 [95% CI 0.08 to 0.30] mL/minute, or approximately 30%. Among the PROs, sticky saliva symptoms were reduced, with a -20.0 [95% CI -37.3 to -2.7] units.
    Interpretation: In conclusion, this study is the first to present long-term follow-up outcomes of allogeneic ASC treatment as a therapeutic option for radiation-induced xerostomia. The study found that ASC treatment appears safe, and there were no indications of adverse immune responses at the 3-year follow-up. Further studies are warranted to evaluate the findings in larger settings.
    Language English
    Publishing date 2024-04-05
    Publishing country England
    Document type Journal Article
    ZDB-ID 2642270-0
    ISSN 2157-6580 ; 2157-6580
    ISSN (online) 2157-6580
    ISSN 2157-6580
    DOI 10.1093/stcltm/szae017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Gene therapy and angiogenesis in patients with coronary artery disease.

    Kastrup, Jens

    Expert review of cardiovascular therapy

    2010  Volume 8, Issue 8, Page(s) 1127–1138

    Abstract: Not all patients with severe coronary artery disease can be treated satisfactorily with current recommended medications and revascularization techniques. Various vascular growth factors have the potential to induce angiogenesis in ischemic tissue. ... ...

    Abstract Not all patients with severe coronary artery disease can be treated satisfactorily with current recommended medications and revascularization techniques. Various vascular growth factors have the potential to induce angiogenesis in ischemic tissue. Clinical trials have only evaluated the effect of VEGF and FGF in patients with coronary artery disease. The initial small and unblinded studies with either recombinant growth factor proteins or genes encoding growth factors were encouraging, demonstrating both clinical improvement and evidence of angiogenesis. However, subsequent larger double-blind placebo-controlled trials could not confirm the initial high efficacy of either the growth factor protein or the gene therapy approaches observed in earlier small trials. The clinical studies so far have all been without any gene-related serious adverse events. Future trials will focus on whether an improvement in clinical results can be obtained with a cocktail of growth factors or by a combination of gene and stem cell therapy in patients with severe coronary artery disease, which cannot be treated effectively with current treatment strategies.
    MeSH term(s) Angiogenesis Inducing Agents/administration & dosage ; Animals ; Clinical Trials as Topic ; Coronary Artery Disease/physiopathology ; Coronary Artery Disease/therapy ; Fibroblast Growth Factors/administration & dosage ; Genetic Therapy/methods ; Humans ; Neovascularization, Physiologic ; Severity of Illness Index ; Vascular Endothelial Growth Factors/administration & dosage
    Chemical Substances Angiogenesis Inducing Agents ; Vascular Endothelial Growth Factors ; Fibroblast Growth Factors (62031-54-3)
    Language English
    Publishing date 2010-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2192343-7
    ISSN 1744-8344 ; 1477-9072
    ISSN (online) 1744-8344
    ISSN 1477-9072
    DOI 10.1586/erc.10.95
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6107: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top